BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu Y, Kwon YS, Labib M, Foran DJ, Singer EA. Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma. Dis Markers 2015;2015:648495. [PMID: 26609190 DOI: 10.1155/2015/648495] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Patel HV, Doppalapudi SK, Singer EA. Taking a SPOP at renal cell carcinoma - unraveling a novel pathway for Tumor progression in clear cell RCC. EBioMedicine 2020;56:102823. [PMID: 32512506 DOI: 10.1016/j.ebiom.2020.102823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Schieda N, Krishna S, Davenport MS. Update on Gadolinium-Based Contrast Agent-Enhanced Imaging in the Genitourinary System. AJR Am J Roentgenol 2019;:1-11. [PMID: 30973785 DOI: 10.2214/AJR.19.21137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yin Q, Xu H, Zhong Y, Ni J, Hu S. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis. BMC Cancer 2022;22:163. [PMID: 35148700 DOI: 10.1186/s12885-022-09239-3] [Reference Citation Analysis]
4 Bao X, Duan J, Yan Y, Ma X, Zhang Y, Wang H, Ni D, Wu S, Peng C, Fan Y, Gao Y, Li X, Chen J, Du Q, Zhang F, Zhang X. Upregulation of long noncoding RNA PVT1 predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. Cancer Biomark 2017;21:55-63. [PMID: 29081406 DOI: 10.3233/CBM-170251] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
5 Vig SVL, Zan E, Kang SK. Imaging for Metastatic Renal Cell Carcinoma. Urol Clin North Am 2020;47:281-91. [PMID: 32600531 DOI: 10.1016/j.ucl.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Reynolds HM, Parameswaran BK, Finnegan ME, Roettger D, Lau E, Kron T, Shaw M, Chander S, Siva S. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma. PLoS One 2018;13:e0202387. [PMID: 30114235 DOI: 10.1371/journal.pone.0202387] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Keller B, Bruynzeel AME, Tang C, Swaminath A, Kerkmeijer L, Chu W. Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma. Front Oncol 2021;11:634830. [PMID: 34046341 DOI: 10.3389/fonc.2021.634830] [Reference Citation Analysis]
8 Yu H, Scalera J, Khalid M, Touret AS, Bloch N, Li B, Qureshi MM, Soto JA, Anderson SW. Texture analysis as a radiomic marker for differentiating renal tumors. Abdom Radiol (NY) 2017;42:2470-8. [PMID: 28421244 DOI: 10.1007/s00261-017-1144-1] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 19.3] [Reference Citation Analysis]
9 Li Q, Liu YJ, Dong D, Bai X, Huang QB, Guo AT, Ye HY, Tian J, Wang HY. Multiparametric MRI Radiomic Model for Preoperative Predicting WHO/ISUP Nuclear Grade of Clear Cell Renal Cell Carcinoma. J Magn Reson Imaging 2020;52:1557-66. [PMID: 32462799 DOI: 10.1002/jmri.27182] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Farber NJ, Kim CJ, Modi PK, Hon JD, Sadimin ET, Singer EA. Renal cell carcinoma: the search for a reliable biomarker. Transl Cancer Res. 2017;6:620-632. [PMID: 28775935 DOI: 10.21037/tcr.2017.05.19] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
11 Varghese BA, Chen F, Hwang DH, Cen SY, Gill IS, Duddalwar VA. Differentiating solid, non-macroscopic fat containing, enhancing renal masses using fast Fourier transform analysis of multiphase CT. Br J Radiol 2018;91:20170789. [PMID: 29888982 DOI: 10.1259/bjr.20170789] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Alhulail AA, Servati M, Ooms N, Akin O, Dincer A, Thomas MA, Dydak U, Emir UE. In Vivo Renal Lipid Quantification by Accelerated Magnetic Resonance Spectroscopic Imaging at 3T: Feasibility and Reliability Study. Metabolites 2022;12:386. [DOI: 10.3390/metabo12050386] [Reference Citation Analysis]
13 Sun D, Lu Q, Wei C, Li Y, Zheng Y, Hu B. Differential diagnosis of <3 cm renal tumors by ultrasonography: a rapid, quantitative, elastography self-corrected contrast-enhanced ultrasound imaging mode beyond screening. Br J Radiol 2020;93:20190974. [PMID: 32479108 DOI: 10.1259/bjr.20190974] [Reference Citation Analysis]
14 Feng G, Huang HB, Ye XB, Zhang P, Huang JJ, Huang LZ, Cheng L, Pu C, Li G. CD146 Promoter Polymorphism (rs3923594) Is Associated with Recurrence of Clear Cell Renal Cell Carcinoma in Chinese Population. Dis Markers 2017;2017:2543059. [PMID: 28626293 DOI: 10.1155/2017/2543059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Modi PK, Farber NJ, Singer EA. Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma. Transl Cancer Res. 2016;5:S76-S80. [PMID: 27540511 DOI: 10.21037/tcr.2016.06.05] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
16 Spraggins JM, Rizzo DG, Moore JL, Noto MJ, Skaar EP, Caprioli RM. Next-generation technologies for spatial proteomics: Integrating ultra-high speed MALDI-TOF and high mass resolution MALDI FTICR imaging mass spectrometry for protein analysis. Proteomics 2016;16:1678-89. [PMID: 27060368 DOI: 10.1002/pmic.201600003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 13.8] [Reference Citation Analysis]
17 Martínez Rodríguez C, Tardáguila de la Fuente G, Villanueva Campos AM. Current management of small renal masses. Radiologia (Engl Ed) 2020;62:167-79. [PMID: 31882171 DOI: 10.1016/j.rx.2019.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Szubert-Franczak AE, Naduk-Ostrowska M, Pasicz K, Podgórska J, Skrzyński W, Cieszanowski A. Intravoxel incoherent motion magnetic resonance imaging: basic principles and clinical applications. Pol J Radiol 2020;85:e624-35. [PMID: 33376564 DOI: 10.5114/pjr.2020.101476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Goyal A, Razik A, Kandasamy D, Seth A, Das P, Ganeshan B, Sharma R. Role of MR texture analysis in histological subtyping and grading of renal cell carcinoma: a preliminary study. Abdom Radiol (NY) 2019;44:3336-49. [PMID: 31300850 DOI: 10.1007/s00261-019-02122-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
20 Corral de la Calle MÁ, Encinas de la Iglesia J, Martín López MR, Fernández Pérez GC, Águeda Del Bas DS. The radiologist's role in the management of papillary renal cell carcinoma. Radiologia 2017;59:100-14. [PMID: 28160948 DOI: 10.1016/j.rx.2016.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]